The April 2025 CJEU ruling: the day 2,000 botanical health claims became illegal in the EU

The CJEU ruled that generic botanical health claims (the "on-hold" list) are prohibited until EFSA evaluation is complete, a process frozen since 2010. This affects every botanical ingredient company selling in the EU. But Article 13.5 allows proprietary claims based on your own clinical evidence. The ruling didn't just block generic claims, it eliminated generic competition. For companies with mechanism data and patents, this is the most advantageous regulatory environment in EU nutraceutical history.Publications of interest:https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex:62023CJ0386, https://pmc.ncbi.nlm.nih.gov/articles/PMC11879797/